US EditionDual Antibody-Drug Conjugates Developed to Target Multiple Cancer Cell Markers
Summary by GeneOnline News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Oncomatryx Secures EU Funding to Advance Antibody-Drug Conjugate Platform - European Biotechnology Magazine
Spanish biotechnology company Oncomatryx Biopharma has been selected for funding under the European Innovation Council (EIC) Accelerator, part of the EU’s Horizon Europe 2021–2027 Research and Innovation Programme. The award includes a €2.5 million grant and a €10 million equity investment, to be deployed in the company’s next financing round to proceed with the proprietary ADC platform. The post Oncomatryx Secures EU Funding to Advance Antibody…
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
